Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
astatine At 211 OKT10-B10
- Development stage
- Phase 1
- Lead developer
- Fred Hutchinson Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Astatine At 211 OKT10-B10 is a radioimmunotherapy agent consisting of the monoclonal antibody OKT10-B10 conjugated to the alpha-emitting radionuclide astatine-211. The antibody component (OKT10-B10) specifically targets CD38, a cell surface antigen highly expressed on multiple myeloma and other hematologic malignancy cells. Upon administration, the drug binds to CD38-positive tumor cells and delivers targeted alpha radiation via astatine-211, resulting in potent cytotoxicity through double-stranded DNA breaks and cell death. This approach allows for selective eradication of malignant plasma cells while sparing most normal tissues. The drug is under investigation primarily for use as part of conditioning regimens prior to autologous or allogeneic stem cell transplantation in patients with multiple myeloma and related disorders[2][3][4][5][8].
- Other names
- astatine-211 anti-CD38 monoclonal antibody OKT10-B10astatine211 anti-CD38 monoclonal antibody OKT10-B10astatine 211 anti-CD38 monoclonal antibody OKT10-B10[211At]OKT10-B10
02
Targets
CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on astatine At 211 OKT10-B10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on astatine At 211 OKT10-B10.